In the matter of Insignia Financial Ltd
Case
•
[2022] NSWSC 488
•26 April 2022
Details
AGLC
Case
Decision Date
In the matter of Insignia Financial Ltd [2022] NSWSC 488
[2022] NSWSC 488
26 April 2022
CaseChat Overview and Summary
Insignia Financial Ltd, a company involved in managed investment schemes, applied to the court for curative orders under the Corporations Act 2001. The application sought to validate the issue and transfer of shares over an 18-year period. These transactions involved millions of shares issued to various controlled entities of the company, which acted as responsible entities, trustees, or custodians for managed investment schemes and trusts. The members and beneficiaries of these schemes and trusts were primarily retail investors. The issue of the shares was challenged on the basis that they were void due to the operation of section 259C of the Corporations Act.
The central legal issue was whether the court should exercise its discretion to validate the invalid share issues and transfers under section 1322(4)(a) of the Corporations Act. This section allows for curative orders to validate certain transactions if it is just and equitable to do so. The court had to consider the potential impact on the numerous retail investors, the complexity and length of the transactions, and whether the invalidity of the share issues had caused any significant prejudice to the company or the investors.
The court determined that granting the curative orders was appropriate. It found that the invalidity of the share issues had not caused any significant prejudice to the company or the investors. The court emphasised the importance of protecting the interests of the retail investors and ensuring the continued operation of the managed investment schemes. The court also considered the long-standing nature of the transactions and the impracticality of undoing them. The application was granted, and the invalid share issues and transfers were validated.
The final orders provided relief to Insignia Financial Ltd, allowing the company to continue operating its managed investment schemes. The court's decision validated the share issues and transfers, providing certainty to the company and its investors. The orders were intended to mitigate any potential harm that might arise from the invalidity of the share transactions.
The central legal issue was whether the court should exercise its discretion to validate the invalid share issues and transfers under section 1322(4)(a) of the Corporations Act. This section allows for curative orders to validate certain transactions if it is just and equitable to do so. The court had to consider the potential impact on the numerous retail investors, the complexity and length of the transactions, and whether the invalidity of the share issues had caused any significant prejudice to the company or the investors.
The court determined that granting the curative orders was appropriate. It found that the invalidity of the share issues had not caused any significant prejudice to the company or the investors. The court emphasised the importance of protecting the interests of the retail investors and ensuring the continued operation of the managed investment schemes. The court also considered the long-standing nature of the transactions and the impracticality of undoing them. The application was granted, and the invalid share issues and transfers were validated.
The final orders provided relief to Insignia Financial Ltd, allowing the company to continue operating its managed investment schemes. The court's decision validated the share issues and transfers, providing certainty to the company and its investors. The orders were intended to mitigate any potential harm that might arise from the invalidity of the share transactions.
Details
Key Legal Topics
Areas of Law
-
Corporate Law & Governance
Legal Concepts
-
Corporate Governance
-
Curative Orders
-
Shares
-
Company Law
Actions
Download as PDF
Download as Word Document
Most Recent Citation
In the matter of Mayne Pharma Group Limited [2024] NSWSC 154
Cases Citing This Decision
4
In the matter of Qantas Airways Limited
[2024] NSWSC 1507
In the matter of Mayne Pharma Group Limited
[2024] NSWSC 154
In the matter of Qantas Airways Limited
[2024] NSWSC 1507
Cases Cited
10
Statutory Material Cited
1